Patent ID: 11891380
Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Field: nan (nan)
Classification: CPC nan | IPC C

Claim 0:
1. A crystalline form of Belumosudil Mesylate designated form M2, which is characterized by data selected from one or more of the following:
(a) an XRPD pattern having peaks at 6.3, 12.8, 15.8, 19.3 and 26.5 degrees 2-theta±0.2 degrees 2-theta;
(b) an XRPD pattern substantially as depicted in FIG. 7;
(c) an XRPD pattern having peaks at 6.3, 12.8, 15.8, 19.3 and 26.5 degrees 2-theta±0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 7.8, 20.4, 23.7, 25.1 and 27.4 degrees two theta±0.2 degrees two theta;
(d) an X-ray powder diffraction pattern having peaks at 6.3, 7.8, 12.8, 15.8, 19.3, 20.4, 23.7, 25.1, 26.5 and 27.4 degrees 2-theta±0.2 degrees 2-theta;
(e) a solid state 13C NMR spectrum with characteristic peaks at 156.1, 132.7, 135.5, 119.8 and 110.9 ppm±0.2 ppm;
(f) a solid state 13C NMR spectrum having the following chemical shift absolute differences from reference peak at 166.9 ppm±1 ppm: 10.8, 34.2, 36.4, 47.1 and 56.0 ppm±0.1 ppm;
(g) a solid state 13C NMR spectrum substantially as depicted in FIG. 19, 20 or 21; and
(h) combinations of these data.